

HAIR-AN syndrome, ovarian hyperthecosis, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility, androgen-producing tumors.

12. A method for suppressing testosterone production in a mammal comprising administering to the mammal an effective amount of a neurokinin-3 receptor antagonist.

13. A method of suppressing the production of luteinizing hormone in a mammal comprising administering to the mammal an effective amount of a neurokinin-3 receptor antagonist.

B1 14. A method for the treatment and/or prophylaxis of a disease in a mammal in need thereof, which disease is characterized by androgenic dependency, comprising administering to the mammal an effective amount of a neurokinin-3 receptor antagonist which inhibits the production of an androgen.

15. A method for suppressing testosterone production in a mammal comprising administering to the mammal an effective amount of a neurokinin-3 receptor antagonist which inhibits the production of testosterone.

16. A method of suppressing the production of luteinizing hormone in a mammal comprising administering to the mammal an effective amount of a neurokinin-3 receptor antagonist which inhibits the production of gonadotropin.--.

REMARKS

This Amendment is made in response to the Official Action mailed December 20, 2002. A request for a two-month extension of time accompanies this Amendment. Claims 1-8 have been canceled and replaced with new claims 9-16. Accordingly, claims 9-16 are now pending in this application. Reconsideration and withdrawal of the objections to, and rejections of this application are respectfully requested in view of the above amendments, and further, in view of the following remarks.

Claims 1-8 have been canceled and replaced with new claims 9-16. Claims 9-16 are directed to a method for treating various diseases characterized by androgenic dependency, a method for suppressing testosterone production, and a method for suppressing the production of luteinizing hormone, with the administration of a neurokinin-3 receptor antagonist. Support for the addition of claims 9-16 is found in the claims and specification as originally filed. No new matter has been added as a result of new claims 9-16.